Malcolm Salter
Director/Board Member bei C4 THERAPEUTICS, INC.
Vermögen: 92 975 $ am 31.03.2024
Profil
Malcolm S.
Salter is currently serving as an Independent Director at C4 Therapeutics, Inc. since 2015, as well as a Director at Raqia Therapeutics, Inc. since 2020, NextRNA Therapeutics, Inc. since 2021, and AI Proteins, Inc. since 2022.
Additionally, he holds a position as a Principal at Harvard Business School.
Previously, he served as the President of Mars & Co. Consulting, Inc. from 1986 to 2006 and as a Trustee at Dana-Farber Cancer Institute, Inc. Mr. Salter obtained his undergraduate, graduate, and doctorate degrees from Harvard University and holds an MBA from Harvard Business School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
C4 THERAPEUTICS, INC.
0,02% | 15.06.2023 | 11 380 ( 0,02% ) | 92 975 $ | 31.03.2024 |
Aktive Positionen von Malcolm Salter
| Unternehmen | Position | Beginn |
|---|---|---|
| C4 THERAPEUTICS, INC. | Director/Board Member | 01.12.2015 |
| Harvard Business School | Corporate Officer/Principal | - |
| Raqia Therapeutics, Inc. | Director/Board Member | 01.09.2020 |
NextRNA Therapeutics, Inc.
 NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | Director/Board Member | 01.02.2021 |
AI Proteins, Inc.
 AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | Director/Board Member | 01.01.2022 |
Ehemalige bekannte Positionen von Malcolm Salter
| Unternehmen | Position | Ende |
|---|---|---|
Mars & Co. Consulting, Inc.
 Mars & Co. Consulting, Inc. Miscellaneous Commercial ServicesCommercial Services Mars & Co. The private company is based in Greenwich, CT. Consulting, Inc. is a strategy consulting firm. | President | 01.01.2006 |
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Director/Board Member | - |
Ausbildung von Malcolm Salter
| Harvard University | Doctorate Degree |
| Harvard Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| C4 THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Health Services |
Mars & Co. Consulting, Inc.
Mars & Co. Consulting, Inc. Miscellaneous Commercial ServicesCommercial Services Mars & Co. The private company is based in Greenwich, CT. Consulting, Inc. is a strategy consulting firm. | Commercial Services |
| Raqia Therapeutics, Inc. | |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | Health Technology |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | Health Technology |
